Skip to main content

Our Journey
Our Technology
Pipeline

Leadership
Investors
Get in Touch

Press Releases

Overview
Press Releases
Events
Presentations
Corporate Governance
Analyst Coverage
Stock Information
SEC Filings
Investor FAQs

Investor Contact

Jill Steier
Executive Director, Investor Relations & Corporate Communications
Jill.Steier@kalarx.com
781-996-5252

Hannah Deresiewicz
hannah.deresiewicz@sternir.com
212-362-1200

Press Releases

Keyword Search

Year

Oct 22, 2021

Kala Pharmaceuticals Reports Inducement Grant Under NASDAQ Listing Rule 5635(c)(4)

Oct 18, 2021

Kala Pharmaceuticals Announces Appointment of C. Daniel Myers to Board of Directors

Sep 21, 2021

Kala Pharmaceuticals Reports Inducement Grant Under NASDAQ Listing Rule 5635(c)(4)

Sep 07, 2021

Kala Pharmaceuticals to Present at Upcoming Investor Conferences in September 2021

Aug 18, 2021

Kala Pharmaceuticals Reports Inducement Grant Under NASDAQ Listing Rule 5635(c)(4)

Aug 05, 2021

Kala Pharmaceuticals Reports Second Quarter 2021 Financial Results and Provides Corporate Update

Aug 04, 2021

Kala Pharmaceuticals to Present at Upcoming Investor Conferences in August

Jul 29, 2021

Kala Pharmaceuticals to Report Second Quarter 2021 Financial Results and Host Conference Call

Jul 29, 2021

Kala Pharmaceuticals to Report Second Quarter 2021 Financial Results and Host Conference Call

Jul 19, 2021

Kala Pharmaceuticals Reports Inducement Grant Under NASDAQ Listing Rule 5635(c)(4)

Jul 19, 2021

Kala Pharmaceuticals Reports Inducement Grant Under NASDAQ Listing Rule 5635(c)(4)

Jun 18, 2021

Kala Pharmaceuticals Reports Inducement Grant Under NASDAQ Listing Rule 5635(c)(4)

Jun 03, 2021

Kala Pharmaceuticals Announces EYSUVIS® Now Covered by OptumRx

May 27, 2021

Kala Pharmaceuticals to Present at Jefferies 2021 Virtual Healthcare Conference

May 20, 2021

Kala Pharmaceuticals Reports Inducement Grant Under NASDAQ Listing Rule 5635(c)(4)

May 06, 2021

Kala Pharmaceuticals to Present at BofA Securities 2021 Healthcare Conference

May 05, 2021

Kala Pharmaceuticals Reports First Quarter 2021 Financial Results and Provides Corporate Update

Apr 28, 2021

Kala Pharmaceuticals to Report First Quarter 2021 Financial Results and Host Conference Call

Mar 18, 2021

Kala Pharmaceuticals Reports Inducement Grant Under NASDAQ Listing Rule 5635(c)(4)

Mar 16, 2021

Kala Pharmaceuticals Announces Preferred Position for EYSUVIS™ on Cigna

Mar 02, 2021

Kala Pharmaceuticals to Present at Upcoming Investor Conferences in March

Feb 25, 2021

Kala Pharmaceuticals Reports Fourth Quarter and Full Year 2020 Financial Results and Provides Corporate Update

Feb 18, 2021

Kala Pharmaceuticals to Report Fourth Quarter and Full Year 2020 Financial Results and Host Conference Call

Feb 17, 2021

Kala Pharmaceuticals Reports Inducement Grant Under NASDAQ Listing Rule 5635(c)(4)

Feb 16, 2021

Kala Pharmaceuticals Announces EYSUVIS™ Now Covered by Express Scripts

Jan 20, 2021

Kala Pharmaceuticals Reports Inducement Grant Under NASDAQ Listing Rule 5635(c)(4)

Jan 07, 2021

Kala Pharmaceuticals Announces Availability of EYSUVIS™ for the Treatment of Dry Eye Disease and Provides Update on Development Pipeline

Jan 04, 2021

Kala Pharmaceuticals to Present at Upcoming Investor Conferences in January

Our Journey
Our Technology
Pipeline
Leadership
- Management Team
- Board of Directors
Investors
Get in Touch

©2021 Kala Pharmaceuticals All rights reserved. AMPPLIFY is a trademark and INVELTYS is a registered trademark of Kala Pharmaceuticals.
US-INV-1900184 January 2021

Terms of Use Privacy Statement Accessibility Policy